EPZ-719 is a highly selective and potent inhibitor of SETD2, a novel compound known for its ability to inhibit the enzymatic activity of SETD2 (IC50 = 0.005 μM). This compound displays a remarkable selectivity over other histone methyltransferases, making it a promising candidate for targeted therapeutic applications in the field of epigenetic research.